Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Tracks quality of life in patients with advanced prostate cancer receiving lutetium treatment

Observes routine care with lutetium vipivotide tetraxetan in advanced prostate cancer.

Plain-language title generated from the registry record
Registry title: Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Key facts

Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz, Cologne, Cottbus, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt (Oder), Fulda, Halle, Herford, Homburg, Jena, Konstanz, Leipzig, Ludwigshafen, Magdeburg, Mainz, Marburg, Munich, Nuremberg, Regensburg, Rostock, Stuttgart, Trier, Tübingen, Ulm, and Würzburg, GermanySee the 35 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with metastatic castration resistant prostate cancer who are starting lutetium (177Lu) vipivotide tetraxetan in routine care. It follows their quality of life.

Age
18 years or older (up to 99 years).
Sex
Men only.
Disease stage
Metastatic castration resistant prostate cancer (mCRPC).
Earlier treatment
The doctor has decided to start lutetium (177Lu) vipivotide tetraxetan as per the local label. People can join before cycle 1 or within 2 weeks after cycle 1.

Main reasons for not taking part

  • Taking part in any investigational trial at the same time
  • Taking part in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan at the same time

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Source: NCT06517719, who can take part

Where in Germany

  • AachenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • AugsburgHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • BerlinHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Bielefeld, North Rhine-WestphaliaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Bonn, North Rhine-WestphaliaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Braunschweig, Lower SaxonyHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • ChemnitzHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Cologne, North Rhine-WestphaliaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Cottbus, BrandenburgHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Dortmund, North Rhine-WestphaliaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Dresden, SaxonyHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Erfurt, ThuringiaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • ErlangenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • EssenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Frankfurt (Oder), BrandenburgHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • FuldaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Halle, Saxony-AnhaltHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • HerfordHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • HomburgHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Jena, ThuringiaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Konstanz, Baden-WurttembergHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Leipzig, SaxonyHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Ludwigshafen, GermanyHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • MagdeburgHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • MainzHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Marburg, HesseHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Munich, BavariaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Nuremberg, BavariaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Regensburg, BavariaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • RostockHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • StuttgartHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • TrierHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • TübingenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • UlmHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Würzburg, BavariaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Novartis Pharmaceuticals
Trial code
NCT06517719
Record updated
13 July 2026
Original description
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.Read full original descriptionShow less

Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study

The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.

Inclusion: All patients must meet the following inclusion criteria during the identification period:; Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1; ≥ 18 years old at the time of enrollment; Written informed consent must be obtained prior to any data collection; Willing to participate in Quality of Life post treatment date collection for 1 year.

Exclusion: Patients must not meet the following exclusion criterion during the identification period:; Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan.

ClinicalTrials.gov NCT06517719